Benitec Biopharma Inc. (BNTC) stock
BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/30
$8.54−0.50 (-5.53%)
Close on Nov 16, 2026Market cap $297.90MP/E –Yield –
Benitec Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Benitec Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$51.13M. For fiscal 2026 it was -$51.13M. The highest annual figure on record is $2.74M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$51.13M | – |
| FY2025 | Jun 30, 2025 | -$41.70M | – |
| FY2024 | Jun 30, 2024 | -$22.40M | – |
| FY2023 | Jun 30, 2023 | -$18.95M | – |
| FY2022 | Jun 30, 2022 | -$17.69M | – |
| FY2021 | Jun 30, 2021 | -$13.37M | – |
| FY2020 | Jun 30, 2020 | -$8.09M | -395.2% |
| FY2019 | Jun 30, 2019 | $2.74M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$14.41M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$13.57M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$13.36M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$9.79M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$9.82M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$15.32M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$10.79M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$5.77M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$5.52M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$4.12M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$6.91M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$5.86M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$4.53M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$4.31M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$5.57M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$4.54M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$4.73M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$3.41M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$4.78M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$4.77M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$3.80M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$3.73M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$3.19M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$2.65M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$2.85M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$2.06M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$2.06M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$1.12M | – |
See a number that looks wrong?